Altered expression of 3-betahydroxysterol delta-24-reductase/selective Alzheimer’s disease indicator-1 gene in Huntington’s disease models
- 148 Downloads
3-betahydroxysterol delta-24-reductase (DHCR24), also called selective Alzheimer’s disease indicator-1, is a crucial enzyme in cholesterol biosynthesis with neuroprotective properties that is downregulated in brain areas affected by Alzheimer’s disease.
In the present study, we investigated modifications of DHCR24 expression in models of Huntington’s disease (HD), a neurodegenerative disorder caused by a polyglutamine expansion in huntingtin (Htt) protein that induces degeneration of cerebral cortex and striatum as well as lateral hypothalamic abnormality.
Basal expression of DHCR24 and its modulation after oxidative stress were evaluated in rat striatal precursors cells (ST14A) transfected with wild-type (Htt) or mutant Htt (mHtt) and in brain tissue of an HD mouse model (R6/2).
The results showed that DHCR24 transcript levels were decreased in ST14A cells expressing mHtt and in the brain of symptomatic R6/2 mice, but were significantly increased in ST14A cells overexpressing wild-type Htt. In addition, we demonstrated that, in the striatal precursors, the decrease of DHCR24 expression in response to oxidative stress was modified according to the presence of Htt or of its mutant form. Preliminary results indicated a modification of DHCR24 expression in post-mortem brain samples of HD patients.
In conclusion, these results support the hypothesis of a possible role of DHCR24 in HD.
KeywordsDHCR24 Neurodegeneration Cholesterol Oxidative stress Huntingtin Seladin-1
Ribosomal 18S subunit
This study was supported by Ministero Istruzione Università e Ricerca (MIUR) (R.M., A.P.), Ente Cassa di Risparmio di Firenze and from Regione Toscana “Bando Salute 2009″, Telethon Foundation (R.M., M.G.). The authors thank Dr.Richard Quinton (Newcastle, UK) and Dr. Francesca Fusco (Rome) for the support in critical reading of the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
- 32.Quinti L, Chopra V, Rotili D, et al. (2010) Evaluation of histone deacetylases as drug targets in Huntington’s disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr 2. doi: 10.1371/currents.RRN1172
- 35.Kuhn A, Goldstein DR, Hodges A et al (2007) Mutant huntingtin’s effects on striatal gene expression in mice recapitulate changes observed in human Huntington’s disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16:1845–1861PubMedCrossRefGoogle Scholar
- 36.Sarchielli E, Marini M, Ambrosini S, et al. (2014) Multifaceted roles of BDNF and FGF2 in human striatal primordium development. An in vitro study. Exp Neurol 257C:130–147Google Scholar